메뉴 건너뛰기




Volumn 12, Issue , 2016, Pages 57-67

Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: A systematic review

Author keywords

Cognition; First episode psychosis; Long term outcome; Relapse; Remission; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

EID: 84954435264     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S96392     Document Type: Article
Times cited : (81)

References (46)
  • 1
    • 13044268459 scopus 로고    scopus 로고
    • Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder
    • Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247.
    • (1999) Arch Gen Psychiatry , vol.56 , Issue.3 , pp. 241-247
    • Robinson, D.1    Woerner, M.G.2    Alvir, J.M.3
  • 2
    • 0032073383 scopus 로고    scopus 로고
    • The natural history and pathophysiology of treatment resistant schizophrenia
    • Sheitman BB, Lieberman JA. The natural history and pathophysiology of treatment resistant schizophrenia. J Psychiatr Res. 1998;32(3-4): 143-150.
    • (1998) J Psychiatr Res , vol.32 , Issue.3-4 , pp. 143-150
    • Sheitman, B.B.1    Lieberman, J.A.2
  • 3
    • 0031918239 scopus 로고    scopus 로고
    • The development of treatment resistance in patients with schizophrenia: A clinical and pathophysiologic perspective
    • Lieberman JA, Sheitman B, Chakos M, et al. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J Clin Psychopharmacol. 1998;18(2 suppl 1): 20S-24S.
    • (1998) J Clin Psychopharmacol , vol.18 , Issue.18 , pp. 20-24
    • Lieberman, J.A.1    Sheitman, B.2    Chakos, M.3
  • 4
    • 84860311080 scopus 로고    scopus 로고
    • Long-term follow-up of the TIPS early detection in psychosis study: Effects on 10-year outcome
    • Hegelstad WT, Larsen TK, Auestad B, et al. Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry. 2012;169(4):374-380.
    • (2012) Am J Psychiatry , vol.169 , Issue.4 , pp. 374-380
    • Hegelstad, W.T.1    Larsen, T.K.2    Auestad, B.3
  • 5
    • 84905666445 scopus 로고    scopus 로고
    • Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: Systematic review and meta-analysis
    • Penttila M, Jaaskelainen E, Hirvonen N, et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2014;205(2):88-94.
    • (2014) Br J Psychiatry , vol.205 , Issue.2 , pp. 88-94
    • Penttila, M.1    Jaaskelainen, E.2    Hirvonen, N.3
  • 6
    • 79955368780 scopus 로고    scopus 로고
    • Preventing the second episode: A systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis
    • Alvarez-Jimenez M, Parker AG, Hetrick SE, et al. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull. 2011;37(3):619-630.
    • (2011) Schizophr Bull , vol.37 , Issue.3 , pp. 619-630
    • Alvarez-Jimenez, M.1    Parker, A.G.2    Hetrick, S.E.3
  • 7
    • 84873462527 scopus 로고    scopus 로고
    • The nature of relapse in schizophrenia
    • Emsley R, Chiliza B, Asmal L, et al. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.
    • (2013) BMC Psychiatry , vol.13 , pp. 50
    • Emsley, R.1    Chiliza, B.2    Asmal, L.3
  • 8
    • 84861585734 scopus 로고    scopus 로고
    • Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis
    • Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-2071.
    • (2012) Lancet , vol.379 , Issue.9831 , pp. 2063-2071
    • Leucht, S.1    Tardy, M.2    Komossa, K.3
  • 10
    • 84892865012 scopus 로고    scopus 로고
    • Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review
    • Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152(2-3):408-414.
    • (2014) Schizophr Res , vol.152 , Issue.2-3 , pp. 408-414
    • Zipursky, R.B.1    Menezes, N.M.2    Streiner, D.L.3
  • 11
    • 80052632040 scopus 로고    scopus 로고
    • Remission and recovery during the first outpatient year of the early course of schizophrenia
    • Ventura J, Subotnik KL, Guzik LH, et al. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res. 2011;132(1):18-23.
    • (2011) Schizophr Res , vol.132 , Issue.1 , pp. 18-23
    • Ventura, J.1    Subotnik, K.L.2    Guzik, L.H.3
  • 12
    • 0034029845 scopus 로고    scopus 로고
    • Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the “right stuff”?
    • Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2000;26(1):119-136.
    • (2000) Schizophr Bull , vol.26 , Issue.1 , pp. 119-136
    • Green, M.F.1    Kern, R.S.2    Braff, D.L.3
  • 13
    • 58149136847 scopus 로고    scopus 로고
    • IQ as a predictor of functional outcome in schizophrenia: A longitudinal, four-year study of first-episode psychosis
    • Leeson VC, Barnes TR, Hutton SB, et al. IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr Res. 2009;107(1):55-60.
    • (2009) Schizophr Res , vol.107 , Issue.1 , pp. 55-60
    • Leeson, V.C.1    Barnes, T.R.2    Hutton, S.B.3
  • 14
    • 1542313966 scopus 로고    scopus 로고
    • Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder
    • Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473-479.
    • (2004) Am J Psychiatry , vol.161 , Issue.3 , pp. 473-479
    • Robinson, D.G.1    Woerner, M.G.2    McMeniman, M.3
  • 16
    • 84859002685 scopus 로고    scopus 로고
    • Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: Randomised controlled trial
    • Chen EY, Hui CL, Lam MM, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ. 2010;341:c4024.
    • (2010) BMJ
    • Chen, E.Y.1    Hui, C.L.2    Lam, M.M.3
  • 17
    • 55849131073 scopus 로고    scopus 로고
    • Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: A study with risperidone long-acting injection
    • Emsley R, Oosthuizen P, Koen L, et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol. 2008;23(6):325-331.
    • (2008) Int Clin Psychopharmacol , vol.23 , Issue.6 , pp. 325-331
    • Emsley, R.1    Oosthuizen, P.2    Koen, L.3
  • 18
    • 0037712923 scopus 로고    scopus 로고
    • Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine
    • Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28(5):995-1003.
    • (2003) Neuropsychopharmacology , vol.28 , Issue.5 , pp. 995-1003
    • Lieberman, J.A.1    Phillips, M.2    Gu, H.3
  • 19
    • 21044457943 scopus 로고    scopus 로고
    • Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial
    • Schooler N
    • Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162(5):947-953.
    • (2005) Am J Psychiatry , vol.162 , Issue.5 , pp. 947-953
  • 20
    • 34249715417 scopus 로고    scopus 로고
    • Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: Relapse rates and functional outcome
    • Wunderink L, Nienhuis FJ, Sytema S, et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68(5): 654-661.
    • (2007) J Clin Psychiatry , vol.68 , Issue.5 , pp. 654-661
    • Wunderink, L.1    Nienhuis, F.J.2    Sytema, S.3
  • 21
    • 67049161211 scopus 로고    scopus 로고
    • Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: A randomized, controlled 1-year follow-up comparison
    • Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry. 2009;70(5):717-729.
    • (2009) J Clin Psychiatry , vol.70 , Issue.5 , pp. 717-729
    • Crespo-Facorro, B.1    Rodriguez-Sanchez, J.M.2    Perez-Iglesias, R.3
  • 22
    • 67649394307 scopus 로고    scopus 로고
    • Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis
    • Cuesta MJ, Jalon EG, Campos MS, et al. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. Br J Psychiatry. 2009;194(5):439-445.
    • (2009) Br J Psychiatry , vol.194 , Issue.5 , pp. 439-445
    • Cuesta, M.J.1    Jalon, E.G.2    Campos, M.S.3
  • 23
    • 66949133915 scopus 로고    scopus 로고
    • Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST)
    • Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009;166(6):675-682.
    • (2009) Am J Psychiatry , vol.166 , Issue.6 , pp. 675-682
    • Davidson, M.1    Galderisi, S.2    Weiser, M.3
  • 24
    • 30944460855 scopus 로고    scopus 로고
    • Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis
    • Keefe RS, Seidman LJ, Christensen BK, et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol Psychiatry. 2006;59(2):97-105.
    • (2006) Biol Psychiatry , vol.59 , Issue.2 , pp. 97-105
    • Keefe, R.S.1    Seidman, L.J.2    Christensen, B.K.3
  • 25
    • 34547218379 scopus 로고    scopus 로고
    • Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison
    • Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1061-1071.
    • (2007) Am J Psychiatry , vol.164 , Issue.7 , pp. 1061-1071
    • Keefe, R.S.1    Sweeney, J.A.2    Gu, H.3
  • 26
    • 84941259017 scopus 로고    scopus 로고
    • Cognitive performance during the first year of treatment in first-episode schizophrenia: A case-control study
    • Olivier MR, Killian S, Chiliza B, et al. Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study. Psychol Med. 2015;45(13):2873-2883.
    • (2015) Psychol Med , vol.45 , Issue.13 , pp. 2873-2883
    • Olivier, M.R.1    Killian, S.2    Chiliza, B.3
  • 27
    • 0034095251 scopus 로고    scopus 로고
    • Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia
    • Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57(3):249-258.
    • (2000) Arch Gen Psychiatry , vol.57 , Issue.3 , pp. 249-258
    • Purdon, S.E.1    Jones, B.D.2    Stip, E.3
  • 28
    • 0037012134 scopus 로고    scopus 로고
    • A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia
    • Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1):16-22.
    • (2002) N Engl J Med , vol.346 , Issue.1 , pp. 16-22
    • Csernansky, J.G.1    Mahmoud, R.2    Brenner, R.3
  • 29
    • 77958009877 scopus 로고    scopus 로고
    • Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: Results of a long-term, open-label, randomized clinical trial
    • Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367-2377.
    • (2010) Neuropsychopharmacology , vol.35 , Issue.12 , pp. 2367-2377
    • Gaebel, W.1    Schreiner, A.2    Bergmans, P.3
  • 30
    • 9144237416 scopus 로고    scopus 로고
    • Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
    • Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;6(4):325-337.
    • (2003) Int J Neuropsychopharmacol , vol.6 , Issue.4 , pp. 325-337
    • Kasper, S.1    Lerman, M.N.2    McQuade, R.D.3
  • 31
    • 0141828595 scopus 로고    scopus 로고
    • Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study
    • Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003;64(9):1048-1056.
    • (2003) J Clin Psychiatry , vol.64 , Issue.9 , pp. 1048-1056
    • Pigott, T.A.1    Carson, W.H.2    Saha, A.R.3
  • 32
    • 34249329193 scopus 로고    scopus 로고
    • Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms
    • Ruhrmann S, Kissling W, Lesch OM, et al. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(5):1012-1022.
    • (2007) Prog Neuropsychopharmacol Biol Psychiatry , vol.31 , Issue.5 , pp. 1012-1022
    • Ruhrmann, S.1    Kissling, W.2    Lesch, O.M.3
  • 33
    • 84883476426 scopus 로고    scopus 로고
    • Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: An open-label, randomized, controlled, pilot study
    • Takeuchi H, Suzuki T, Remington G, et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull. 2013;39(5):993-998.
    • (2013) Schizophr Bull , vol.39 , Issue.5 , pp. 993-998
    • Takeuchi, H.1    Suzuki, T.2    Remington, G.3
  • 34
    • 0036268294 scopus 로고    scopus 로고
    • Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    • Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159(6):1018-1028.
    • (2002) Am J Psychiatry , vol.159 , Issue.6 , pp. 1018-1028
    • Bilder, R.M.1    Goldman, R.S.2    Volavka, J.3
  • 35
    • 77956913292 scopus 로고    scopus 로고
    • Antipsychotic medication and social cue recognition in chronic schizophrenia
    • Roberts DL, Penn DL, Corrigan P, et al. Antipsychotic medication and social cue recognition in chronic schizophrenia. Psychiatry Res. 2010; 178(1):46-50.
    • (2010) Psychiatry Res , vol.178 , Issue.1 , pp. 46-50
    • Roberts, D.L.1    Penn, D.L.2    Corrigan, P.3
  • 36
    • 1642283731 scopus 로고    scopus 로고
    • Practice guideline for the treatment of patients with schizophrenia, second edition
    • Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 suppl):1-56.
    • (2004) Am J Psychiatry , vol.161 , Issue.2 , pp. 1-56
    • Lehman, A.F.1    Lieberman, J.A.2    Dixon, L.B.3
  • 37
    • 0035154103 scopus 로고    scopus 로고
    • Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia
    • Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001;158(11):1835-1842.
    • (2001) Am J Psychiatry , vol.158 , Issue.11 , pp. 1835-1842
    • Gitlin, M.1    Nuechterlein, K.2    Subotnik, K.L.3
  • 38
    • 79958233416 scopus 로고    scopus 로고
    • A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia
    • Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603-609.
    • (2011) Am J Psychiatry , vol.168 , Issue.6 , pp. 603-609
    • Tiihonen, J.1    Haukka, J.2    Taylor, M.3
  • 39
    • 7544251500 scopus 로고    scopus 로고
    • Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates
    • Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157(4):549-559.
    • (2000) Am J Psychiatry , vol.157 , Issue.4 , pp. 549-559
    • Bilder, R.M.1    Goldman, R.S.2    Robinson, D.3
  • 40
    • 23944435882 scopus 로고    scopus 로고
    • Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia
    • Hoff AL, Svetina C, Shields G, et al. Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophr Res. 2005;78(1):27-34.
    • (2005) Schizophr Res , vol.78 , Issue.1 , pp. 27-34
    • Hoff, A.L.1    Svetina, C.2    Shields, G.3
  • 41
    • 84873527062 scopus 로고    scopus 로고
    • A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia
    • Wang CH, Li Y, Yang J, et al. A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia. Schizophr Res. 2013;144(1-3):129-135.
    • (2013) Schizophr Res , vol.144 , Issue.1-3 , pp. 129-135
    • Wang, C.H.1    Li, Y.2    Yang, J.3
  • 42
    • 84904804929 scopus 로고    scopus 로고
    • Biological insights from 108 schizophrenia-associated genetic loci
    • Schizophrenia Working Group of the Psychiatric Genomics C
    • Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421-427.
    • (2014) Nature , vol.511 , Issue.7510 , pp. 421-427
  • 43
    • 84925130699 scopus 로고    scopus 로고
    • Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder
    • Maier R, Moser G, Chen GB, et al. Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder. Am J Hum Genet. 2015; 96(2):283-294.
    • (2015) Am J Hum Genet , vol.96 , Issue.2 , pp. 283-294
    • Maier, R.1    Moser, G.2    Chen, G.B.3
  • 44
    • 77952747517 scopus 로고    scopus 로고
    • Portland identification and early referral: A community-based system for identifying and treating youths at high risk of psychosis
    • McFarlane WR, Cook WL, Downing D, et al. Portland identification and early referral: a community-based system for identifying and treating youths at high risk of psychosis. Psychiatr Serv. 2010;61(5): 512-515.
    • (2010) Psychiatr Serv , vol.61 , Issue.5 , pp. 512-515
    • McFarlane, W.R.1    Cook, W.L.2    Downing, D.3
  • 45
    • 77954229336 scopus 로고    scopus 로고
    • Processing speed deficits in schizophrenia: Reexamining the evidence
    • Knowles EE, David AS, Reichenberg A. Processing speed deficits in schizophrenia: reexamining the evidence. Am J Psychiatry. 2010; 167(7):828-835.
    • (2010) Am J Psychiatry , vol.167 , Issue.7 , pp. 828-835
    • Knowles, E.E.1    David, A.S.2    Reichenberg, A.3
  • 46
    • 33947712686 scopus 로고    scopus 로고
    • Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers
    • Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6(4):287-293.
    • (2007) Nat Rev Drug Discov , vol.6 , Issue.4 , pp. 287-293
    • Trusheim, M.R.1    Berndt, E.R.2    Douglas, F.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.